Top 50 Biotechnology Startup Investors in Denmark
A list of 50 angel investors and VC funds that invest in Biotechnology startups based in Denmark. We rank investors based on the number of investments they made in Biotechnology companies from Denmark. We update this investor list every month.Top 50 Biotechnology Startup Investors in Denmark
Investor | Biotechnology Denmark investments |
---|---|
Novo Holdings | 29 |
BioInnovation Institute | 22 |
Vaekstfonden | 15 |
Vaekstfonden | 12 |
Seed Capital | 9 |
Sunstone Life Science Ventures | 9 |
PSV | 7 |
Nordic Foodtech VC | 6 |
Gilde Healthcare | 6 |
Oskare Capital | 4 |
RA Capital Management | 4 |
VF Venture | 4 |
Ysios Capital | 4 |
Per Falholt | 3 |
DSM Venturing | 3 |
Atlantic Labs | 3 |
West Hill Capital | 3 |
Sofinnova Partners | 3 |
ACME Capital | 3 |
EIR Ventures | 3 |
Export and Investment Fund | 3 |
HealthCap | 3 |
Nicholas Francis | 3 |
Thia Ventures | 3 |
Novo Ventures | 2 |
Industrifonden | 2 |
SOSV | 2 |
Aescap Venture | 2 |
Novo Nordisk | 2 |
Lundbeckfonden Ventures | 2 |
Inkef | 2 |
Wellcome Trust | 2 |
Symrise | 2 |
FundersClub | 2 |
Innovations Kapital | 2 |
Johnson & Johnson Development Corporation | 2 |
Innovation Fund Denmark | 2 |
Wellington Partners | 2 |
+ND Capital | 2 |
Karolinska | 2 |
Balderton Capital | 2 |
PINC | 2 |
Giampaolo Cagnin | 2 |
M Ventures | 2 |
Verve Ventures | 2 |
Bruce Linton | 2 |
Northzone | 2 |
CAPNOVA | 2 |
Newtree Impact | 2 |
Blue Horizon Corporation | 2 |
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Convertible Note, Pre-Seed, Debt Financing
- Denmark, Germany, Switzerland
Portfolio highlights
- NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
- TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
- HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Funding Round, Pre-Seed
- Denmark, United States, United Kingdom
Portfolio highlights
- Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
- Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
- kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Funding Round, Pre-Seed
- Denmark, United States, Norway
Portfolio highlights
- Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
- Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
- kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more
Investment focus
- Software, Health Care, SaaS
- Seed, Funding Round, Series A
- Denmark, United States, United Kingdom
Portfolio highlights
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
- Embla — Embla provides an online medical weight loss treatment using prescription drugs and coaching. The company provides patients with evidence-based treatments, digital tools, medication, and coaching to facilitate sustainable weight loss. Embla was founded in 2021 and is headquartered in Copenhagen, Denmark.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.
Show more
Investment focus
- Software, Information Technology, SaaS
- Seed, Pre-Seed, Funding Round
- Denmark, United States, United Kingdom
Portfolio highlights
- spektr — Explore spektr's tailored compliance automation solutions for KYB monitoring, AML compliance, risk management, and more. Try our no-code, customizable platform for free today!
- UltiHash — Data powers breakthroughs. UltiHash is the storage foundation to accelerate them: blazing fast, highly efficient, and built for sustainable long-term growth.
- Yacheng Network — Yacheng Network is a provider of information technology and software services that specializes in offering these services.
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more
Investment focus
- Biotechnology, Life Science, Water
- Seed, Series A, Funding Round
- Finland, Sweden, Denmark
Portfolio highlights
- Enifer — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- NPHarvest — NPHarvest is a company with expertise in organic waste management, wastewater treatment, and nutrient recovery. NPHarvest is a research project aiming to enable efficient and profitable nitrogen recycling from waste flows to the fertilizer market, utilizing energy-efficient hydrophobic membrane stripping and ballasted sedimentation of phosphoruswith lime.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series C, Series B, Series A
- United States, The Netherlands, Germany
Portfolio highlights
- Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Oskare Capital is a venture capital firm.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Pre-Seed, Series A
- Italy, Denmark, United Kingdom
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, China
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- MBX Biosciences — Homepage - MBX Biosciences
- Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more
Investment focus
- Software, Biotechnology, SaaS
- Seed, Funding Round, Series A
- Denmark, United Kingdom, Iceland
Portfolio highlights
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Spain, United States, Switzerland
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
- Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more
Investment focus
- Biotechnology, Robotics, Life Science
- Seed, Pre-Seed, Series A
- Denmark
Portfolio highlights
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more
Investment focus
- Biotechnology, Health Care, Manufacturing
- Series A, Funding Round, Series B
- United States, Canada, Israel
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Pre-Seed
- Germany, Switzerland, United States
Portfolio highlights
- Again — SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock.
- SynthFlow AI — Build AI Agents at Scale. No Coding Required.
- SCRYPT Digital — Your trusted partner for crypto assets
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more
Investment focus
- Information Technology, Software, Health Care
- Seed, Funding Round, Series A
- United Kingdom, Denmark
Portfolio highlights
- Bioomix — Nordic microbes A/S (formerly Bioomix A/S) is a Danish biotech company committed to driving the green transition in agriculture. Our vision is a future where
- ATLANT 3D Nanosystems — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — A Whistleblower Software system made for accountants and lawyers that have clients, the whistleblower software system helps businesses implement a compliant solution that is both secure and transparent. their products are reporting links, case management, partner account they have designed a journey that makes feel safe about the process. AWS ishandling the physical security of the infrastructure, whistleblower software takes the shared responsibility of security between our cloud infrastructure and application seriously.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- deepc — The Radiology AI Platform - Your effortless access to AI
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.
ACME is a venture capital firm investing in iconic founders disrupting massive markets.
Show more
Investment focus
- Software, Health Care, Internet
- Seed, Series A, Series B
- United States, Denmark, Canada
Portfolio highlights
- Muon Space — Earth intelligence for a Safe and Resilient World.
- Again — SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Funding Round
- Denmark, Sweden, United States
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- ArgusEye — ArgusEye - Innovative Sensor Solutions - Real-time monitoring and control of biological systems and processes - Patented sensor technology
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more
Investment focus
- Software, Health Care, SaaS
- Seed, Funding Round, Series A
- Denmark, Ukraine, United States
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
- Again — SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
Nicholas Francis is Co-founder at framebunker
Show more
Investment focus
- SaaS, Robotics, Software
- Seed, Series A
- Denmark, United States
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more
Investment focus
- Biotechnology, Health Care, Food and Beverage
- Series A, Seed, Series B
- United States, France, Denmark
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- Protealis — Sustainable plant proteins for Europe
- Clever Carnivore — Clever Carnivore is a cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, United Kingdom, Switzerland
Portfolio highlights
- INBRACE — Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
- Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
- Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Funding Round, Series A, Seed
- Sweden, United States, Denmark
Portfolio highlights
- Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
- Telness Tech — We help telcos maximize customer happiness and minimize OPEX through automation. Our proprietary, cloud-based, end-to-end BSS/OSS platform is connectivity ready in 64 countries.
- ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more
Investment focus
- Biotechnology, Pharmaceutical, Chemical
- Series A, Series B, Funding Round
- United Kingdom, Austria, Belgium
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series C, Seed
- United States, Denmark, France
Portfolio highlights
- Sundew — Targeting water-borne pests and diseases
- The Sabi — Holistic, all natural skincare and herbal remedies for hormonal balancing. SABI represents a path to feeling well and beautiful, a place for key knowledge transfer and the essential self-care rituals to navigate the female hormonal journey.
- ElevateBio — We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, France
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- LEXEO Therapeutics — LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- The Netherlands, United States, Germany
Portfolio highlights
- Onward — Working to restore movement, independence, and health in people with spinal cord injury.
- Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
- Provable Markets — Our cloud-native ATS, Aurora, offers the only regulated access point to the DTCC SFT Clearing Service
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science.
It was founded in 1936 and headquartered in London, England.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Grant, Series C, Funding Round
- United States, United Kingdom, Germany
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
- Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
About 30,000 products - 6,000 customers in roughly 160 countries. First synthesis of vanillin in 1874.
Show more
Investment focus
- Beauty, Internet, Cosmetics
- Series A, Seed
- United States, Denmark
Portfolio highlights
- Phlur — Phlur brings you fine fragrances created by world-class perfumers, our fragrances are meticulously crafted with modern sensibility and radical transparency.
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- Sunday2Sunday — A haircare brand created for active women that provides quality products to cleanse and refresh textured hair pre- and post-workout.
FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Series A, Funding Round
- United States, Canada, India
Portfolio highlights
- Malibou — Malibou is developing the first all-in-one payroll and HR software for all French startups and SMBs. Malibou is committed to simplifying complex processes so that you can focus on your business.
- Quindar — Satellite Mission Management for startups. Operate faster than your competition.
- Toku — Toku helps companies to automate collections and facilitate payment processes. Toku enables companies to optimize the collection of recurring payments.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Series B, Series C
- Sweden, Denmark, United States
Portfolio highlights
- Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series C, Series B, Funding Round
- United States, United Kingdom, Canada
Portfolio highlights
- CVRx — CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
- Binx Health — Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer
- Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more
Investment focus
- Software, SaaS, Information Technology
- Grant, Pre-Seed, Seed
- Denmark, United States
Portfolio highlights
- Artelize — Discover events, performers and works within classical music, opera, musical, ballet & dance and drama. 214054 events, and 65811 artists and creators.
- Tryp.com — There is always a reason to go! We use artificial intelligence to find the best travel deals at the lowest price. The algorithm compares and connects flights, trains, and buses to create the perfect multidestination trips with matching hotel offers.
- Curvature AI — Grow your revenue with discounts and special offers selected and optimized by AI.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
- Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
- Onward — Working to restore movement, independence, and health in people with spinal cord injury.
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Switzerland, Denmark
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Partillion Bioscience — Unlock your research today with the word's first functional single-cell biology reagent platform. Next generation assay kits for single-cell secretion analysis and more.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Funding Round, Seed, Series A
- Sweden, Denmark, United States
Portfolio highlights
- PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
- OssDsign AB — Giving patients back the life they deserve, Catalyst nanosynthetic bone graft, orthobiologics
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more
Investment focus
- Software, FinTech, Financial Services
- Series B, Series A, Series C
- United Kingdom, United States, Germany
Portfolio highlights
- Attio — Unlock your team's true potential with Attio, the data-driven CRM for modern teams. Manage everything from sales leads through to recruitment pipelines.
- Delli — We're a company just starting out on our mission to make good food accessible and enjoyed by all.
- TILT — TILT app allow users to discover small brands, buy through videos, livestreams, and eard rewards.
PINC invests in attractive start-ups leveraging four major consumer trends: Conscious Consumption, Holistic Health, Personalized Convenience, and Authentic Experiences.
Show more
Investment focus
- Biotechnology, Cooking, Children
- Seed, Pre-Seed, Series A
- Sweden, France, Denmark
Portfolio highlights
- Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
- Improvin' — Improvin' is a sustainability performance platform that helps agri-food companies measure, report and reduce greenhouse gas emissions in their own value chain.
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more
Investment focus
- Biotechnology, Food and Beverage, Plant-Based Foods
- Seed, Pre-Seed
- Italy, Denmark
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Switzerland, United Kingdom
Portfolio highlights
- LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
- Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, Germany, France
Portfolio highlights
- Cubbit — Cubbit is secure encrypted cloud storage with a difference. A distributed cloud that is 100% private and green. Join the Swarm.
- Axelera AI — To accelerate computer vision in edge devices, we offer a powerful, energy-efficient, cost-effective, user-friendly AI hardware and software platform.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more
Investment focus
- Health Care, Cannabis, Biotechnology
- Seed, Post-IPO Equity, Pre-Seed
- Canada, United States, Denmark
Portfolio highlights
- Omura — Discover heat-not-burn technology with Omura's dry herb vaporizer devices. Explore sustainable vaping options for hemp & whole flower CBD.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Martello Technologies — Prioritize and resolve performance problems and optimize the Microsoft 365 and Teams user experience with Martello Vantage DX.
Northzone is a multi-stage venture capital fund that seeks to invest in the healthcare, semiconductors, software, hardware, artificial intelligence, blockchain, and gaming industries.
Show more
Investment focus
- Software, E-Commerce, Information Technology
- Series A, Series B, Seed
- United States, Sweden, United Kingdom
Portfolio highlights
- Reonic — Reonic provides software to accelerate the energy transition in an economically and ecologically feasible way.
- Flower — We enable the energy system of tomorrow by combining pioneering technology with flexible assets, allowing clean energy to power society
- Spring Health — Eliminating barriers to mental healthcare. Clinically-proven technology with world-class providers to deliver precisely what your employees need.
They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more
Investment focus
- Software, Information Technology, Internet
- Funding Round, Seed, Pre-Seed
- Denmark, United States, India
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.
Show more
Investment focus
- Biotechnology
- Seed
- Denmark
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more
Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Seed, Series A, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- WOW EARN — WOW EARN is a decentralized DeFi platform offering Web3 applications including staking, mining, NFT minting, DEX, GameFi, DAO governance, and multi-chain support. Join the future of decentralized finance.
- New School Foods — Whole-muscle, plant-based seafood
- Basecamp Research — Novel proteins from nature. We sample the most extreme and exciting places on the planet to build the world's largest knowledge graph of natural biodiversity.
Investors by industry
Google
Artificial intelligence
Biotech
Climate
Proptech
Consumer
Media (entertainment)
Hardware
Community
Health Care
FinTech
Gaming
Impact
Marketplace
Energy
EdTech
Sustainability
Agriculture (agtech)
Venture Capital
Retail
Art
Fashion
Email
Beauty
Social Media
Infrastructure
Wellness
Social Network
Big Data
Publishing
Medical
Food and Beverage
Manufacturing
Organic Food
Internet
Music
Real Estate
Digital Media
Photography
Legal
B2B
Franchise
Web3
eSports
Oil and Gas
Local
Video Games
Android
Construction
Financial Services
Enterprise Software
Mobile
Finance
Sports
Clean Energy
Fitness
Travel
Payments
Hospitality
Recruiting
Education
Biotechnology
Mobile Advertising
Social
Cannabis
Crowdfunding
Platforms
CleanTech
Automotive
Transportation
Mobile Apps
Wine And Spirits
InsurTech
Enterprise
Medical Device
LGBT
Film
Theatre
Life Science
Renewable Energy
Non Profit
SaaS
Sporting Goods
Restaurants
Celebrity
Software
Social Impact
Cryptocurrency
Facebook
Blockchain
Investors by country
Germany
India
South Korea
Canada
New Zealand
Australia
United Kingdom
United States
Ireland
Japan
Armenia
Brazil
Africa
LATAM
Middle East
Asia
Saudi Arabia
Europe
Singapore
Belize
Spain
Bahrain
Algeria
Vietnam
Barbados
Hungary
Gibraltar
China
Costa Rica
Ethiopia
Oceania
Greece
Indonesia
Finland
Qatar
South Africa
Estonia
Sri Lanka
Kuwait
Ghana
Lithuania
Ecuador
Mali
Philippines
Chile
Jersey
Egypt
Myanmar
Malta
Croatia
Mauritius
Nicaragua
Georgia
Belarus
Italy
Faroe Islands
Denmark
Liechtenstein
Hong Kong
Kenya
France
Cayman Islands
Belgium
Israel
Bermuda
Bulgaria
Liberia
Panama
Czech Republic
Malaysia
Tanzania
Zimbabwe
Slovenia
Lebanon
Tunisia
Russian Federation
Kazakhstan
San Marino
Norway
Ukraine
Serbia
Cambodia
Venezuela
Morocco
Thailand
Peru
Zambia
Uzbekistan
Togo
Mexico
Uruguay
Tajikistan
Senegal
Dominican Republic
Azerbaijan
Namibia
El Salvador
Nigeria
Portugal
Sierra Leone
Turkey
Iraq
Poland
Puerto Rico
Iceland
Taiwan
Seychelles
Uganda
Rwanda
Sweden
United Arab Emirates
Bahamas
Honduras
Luxembourg
Isle of Man
Bolivia
Albania
Bangladesh
Pakistan
Romania
Grenada
Jordan
Argentina
Cameroon
Cyprus
Latvia
Oman
Austria
Switzerland
Colombia
Marshall Islands
Guatemala
Investors in Denmark by industry
Restaurants
Transportation
Social
Media (entertainment)
Big Data
Education
Cryptocurrency
Finance
Food and Beverage
Payments
Mobile Apps
Video Games
Medical
Financial Services
Medical Device
Sports
Social Media
Internet
Fitness
Manufacturing
Art
Music
Blockchain
Mobile
Legal
Software
Enterprise Software
eSports
Travel
Hospitality
Automotive
Platforms
Recruiting
Biotechnology
FinTech
Enterprise
Consumer
Health Care
Biotech
EdTech
Sustainability
Climate
Energy
Impact
Proptech
SaaS
Agriculture (agtech)
Retail
Hardware
Fashion
Beauty
Community
B2B
Sporting Goods
Life Science
Photography
Wellness
Renewable Energy
Gaming
Real Estate
CleanTech
Construction
Web3
Marketplace
Artificial intelligence
Social Network
Social Impact